Date: 2016-01-25
Type of information: Nomination
Compound:
Company: Onxeo (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 25, 2016, Onxeo announced that Prof. Jean-Pierre Kinet, M.D., of Harvard Medical School, and Jean-Pierre Bizzari, M.D., world-renowned experts in oncology with over 20 years of pharma and biotech experience in the United States, have been appointed Observers to the Board of Directors, effective immediately. Their appointments as full board members will be submitted to the shareholders during the next annual
shareholders meeting.
Dr. Bizzari has dedicated his professional life to clinical development, especially in oncology, and has
brought to the market several leading cancer drugs – including Abraxane® (nab-paclitaxel), Eloxatin®
(oxaliplatin), and Taxotere® (docetaxel). During his most recent experience as Executive Vice-President
of Clinical Oncology Development at Celgene, Dr. Bizzari developed hematology and solid tumors
therapeutics, including an HDAC (histone deacetylase) inhibitor.
Dr. Kinet will bring to Onxeo his research expertise in immunology and oncology acquired through various
positions in academia, including his current position as Professor of Pathology at Harvard Medical School
(Boston - USA).
In addition, Mr. Joseph Zakrzewski has been elected Chairman of Onxeo’s Board of Directors, as announced in October 2015. He is replacing Patrick Langlois, who has resigned. Mr. Zakrzewski has more than 25 years of experience in the global healthcare industry with a strong focus in the United States.
Financial terms:
Latest news:
